Efficacy and Safety of Irlanda-2 Association on the Treatment of Common Cold

• Status: Withdrawn
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the clinical efficacy of the drug associations in the treatment of common cold

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMS
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Guaifenesin; Ibuprofen; Loratadine; Phenylpropanolamine

Criteria

Inclusion Criteria:

• Participant within 48 hours of the onset of common cold symptoms: headache, sneezing, sore throat, nasal obstruction, cough, coryza and body pain;

• Signed consent.

Exclusion Criteria:

• Patients with any clinically significant disease that, in the investigator opinion, can´t participate in the study;

• Patients with any laboratory finding or image finding that, in the investigator opinion, can´t participate in the clinical trial;

• Patients with history of hypersensitivity to any of the formula compounds;

• Participation in clinical trial in the year prior to this study;

• Patients with vaccine reaction;

• Patients who have uncontrolled asthma. However, participants in use of pulmonary corticosteroids (alone or in combination with other products) will be allowed if they are in stable dose and diagnosed with controlled asthma;

• Patients with gastroesophageal reflux, gastric or duodenal ulcer or other serious disease of the gastrointestinal tract;

• Patients with diabetes mellitus type I and II;

• Pregnancy or risk of pregnancy and lactating patients;

• Patients in use of drugs that can interfere with flu symptoms evaluation.